Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.

European journal of clinical pharmacology - 1 Mar 2021

Zhu Kong-Xiang, Song Pei-Yuan, He-Li, Li Mu-Peng, Du Yin-Xiao, Ma Qi-Lin, Peng Li-Ming, Chen Xiao-Ping

Abstract excerpt

PURPOSE: Dual antiplatelet therapy with aspirin and clopidogrel is commonly used for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention to prevent stent thrombosis and ischemic events. However, some patients show high on-treatment platelet reactivity (HTPR) during clopidogrel therapy. Genetic factors such as loss-of-function variants of CYP2C19 are validated to increase the risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asian People
Share to Aspirin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Coronary Artery Disease

Share to Cytochrome P-450 CYP2C19

Share to Oxygenases

Share to Platelet Aggregation Inhibitors

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 33089397
DOI: 10.1007/s00228-020-03024-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.PMID 33089397Read ↗

The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.Semantic proximity Read ↗

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.Semantic proximity Read ↗

CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.Semantic proximity Read ↗

CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.Semantic proximity Read ↗

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.Semantic proximity Read ↗

PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.Semantic proximity Read ↗

Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy.Semantic proximity Read ↗

Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.Semantic proximity Read ↗

The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.Semantic proximity Read ↗

Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.Semantic proximity Read ↗

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.Semantic proximity Read ↗

Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.